Heparin has been the standard anticoagulant for over a century, effectively preventing harmful blood clots. However, its use is complicated by a significant side effect: an increased risk of excessive bleeding.
The recent study suggests that a snail-derived compound could mitigate this risk, offering a potential alternative for patients requiring anticoagulation therapy.
If validated through further research and clinical trials, this compound could reshape anticoagulant protocols, enhancing patient safety and treatment outcomes.